

# GREY MATTER ATROPHY IN PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS

Zsigmond Tamás KINCSES<sup>1,2</sup>, Eszter TÓTH<sup>1</sup>, Nóra BANKÓ<sup>1</sup>, Dániel VERÉB<sup>1</sup>, Nikoletta SZABÓ<sup>1,2</sup>, Gergő CSETE<sup>1</sup>, Péter FARAGÓ<sup>1</sup>, András KIRÁLY<sup>1</sup>, Krisztina BENCSEK<sup>1</sup>, László VÉCSEI<sup>1,3</sup>

<sup>1</sup>Department of Neurology, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary

<sup>2</sup>International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic

<sup>3</sup>MTA-SZTE Neuroscience Research Group, Szeged, Hungary

## SZÜRKEÁLLOMÁNYI ATROPHIA SCLEROSIS MULTIPLEXBEN SZENVEDŐ BETEGEK ESETÉBEN

Kincses ZsT, MD, PhD; Tóth E, MD; Bankó N, MD; Veréb D, MD; Szabó N, MD; Csete G, MD; Faragó P, MD; Király A, MD; Bencsik K, MD; Vécsei L, MD

**Ideggyogy Sz 2014;67(9–10):293–300.**

Kapcsolódó



klikk online

White matter lesions are defining characteristics of multiple sclerosis (MS), whereas grey matter involvement is a less recognised attribute. Recent investigations using dedicated imaging approaches have made it possible to depict cortical lesions. Additionally, grey matter atrophy may be estimated using various methods. Several studies have suggested that grey matter atrophy closely correlates to clinical disability. In this review we have collected information on grey matter atrophy in MS and the effect of disease modifying therapies upon brain atrophy.

**Keywords:** multiple sclerosis; atrophy, gray matter; MRI; voxel based morphometry

A fehérállományi laesiók a sclerosis multiplex (SM) meghatározó jellemzői, a szürkeállomány elváltozásai kevésbé ismertek. A megfelelő agyi képalkotó eljárásokkal végzett újabb vizsgálatokban láthatóvá tudták tenni a kérgi elváltozásokat. Emellett különféle módszerekkel felmérhető a szürkeállományi atrophia. Számos vizsgálat eredményei szerint a szürkeállomány atrophiaja szorosan korrelál a klinikai rokkantsággal. Összefoglaljuk az SM-ben megfigyelhető szürkeállományi atrophiaival kapcsolatos információkat és a betegségmódosító terápiák hatását az agyi atrophiaira.

**Kulcsszavak:** sclerosis multiplex, atrophia, szürkeállomány, MRI, voxelalapú morfometria

Correspondent: Zsigmond Tamás KINCSES MD, PhD, Department of Neurology, Albert Szent-Györgyi Clinical Center, University of Szeged; H-6725 Szeged, Semmelweis u. 6.

E-mail: [kincses.zsigmond.tamas@med.u-szeged.hu](mailto:kincses.zsigmond.tamas@med.u-szeged.hu); [www.nepsy.szote.u-szeged.hu/~neuroimaging](http://www.nepsy.szote.u-szeged.hu/~neuroimaging)

[www.elitmed.hu](http://www.elitmed.hu)

Multiple sclerosis (MS) is an inflammatory, neurodegenerative disease. The primary feature of MS is the demyelination paralleled by varying degrees of axonal damage<sup>1</sup>. The focal inflammatory demyelinating lesions in the white matter are not only the hallmarks of the disease, but in vivo demonstration of these lesions with MR imaging is also part of the diagnosis<sup>2</sup>. Recently, it has become clear that grey matter is also adversely affected. This review aims to summarize the recent advances made by studies assessing grey matter atrophy in MS patients for both clinical and scientific purposes.

## Grey matter lesions

Early post-mortem histological studies established the existence of grey matter lesions in MS patients<sup>3–6</sup>. Grey matter lesions are classified as

Types I to IV. Type I lesions, located at the border of the grey and white matter, rarely occur. Type II lesions occur within the cortex. Type III subpial lesions are the most frequent. Type IV lesions cover the full width of the cortex and occur infrequently. While the neuropathological studies<sup>4–9</sup> have provided insight into the cortical pathology, these studies are limited by the inclusion of patients with different disease types and stages, consequently restricting inter-study comparability. Advanced MRI methods may offer an alternative approach to track progression of the grey matter lesions and elucidate their significance in the disease process. With modern MRI sequences, such as the double inversion recovery<sup>10,11</sup> it is possible to detect many more cortical lesions than conventional T2 weighted sequences. However, the detection rate is still only around 20% when compared to neuropathological investigations<sup>12</sup>. Furthermore, the inter-rater agreement in identifying lesions is rather low<sup>13</sup>. Ultra-

high field imaging may facilitate increased sensitivity and specificity of the grey matter lesion detection<sup>13</sup>, although the modality is not widely available.

## Grey matter atrophy

Apart from depicting grey matter lesions MRI investigations are also capable of identifying grey matter atrophy. There are several approaches available to evaluate grey matter atrophy. Apart from manual segmentation, gross grey matter volume can be estimated (cortical with or without subcortical) by automatic segmentation of brain tissue types<sup>14–16</sup>. Another approach for detecting atrophy is by measuring cortical thickness. One of the most common approaches for this is the voxel-wise comparison of intensities (or more precisely the probability of tissue types in individual voxels)<sup>15, 17</sup>. The advantage of this method is that it can identify focal atrophy. However, inter-subject registration is the critical limitation of this method.

MRI studies employing various methodologies agree on the significant grey matter atrophy in MS. The earliest MRI study on gross brain atrophy using manual measurements showed significant brain volume change in MS patients<sup>18</sup>, as confirmed by semi-automatic larger dataset studies<sup>19–22</sup>. Likewise, the brain parenchymal fraction (the ratio of the pre-morbid brain size -measured as intracranial volume- and the brain parenchymal volume) is about 3–5% smaller compared to normal controls<sup>23–25</sup> and considerably smaller in secondary progressive MS<sup>26</sup>. Tissue type segmentation made it possible to identify atrophy in both grey<sup>24, 26–28</sup> and white matter<sup>26, 29</sup>.

Voxel-based morphometry (VBM) studies demonstrated that the grey matter atrophy is not uniform over the cortex (**Table 1**). These studies revealed that the grey matter pathology exhibits considerable heterogeneity in patients, because a clear pattern of grey matter atrophy cannot always be established. Other studies failed to find atrophy in MS patients when compared to controls subjects. *Audoin* and co-workers found no difference between control subjects and relapsing-remitting MS patients early in their disease course. However over two years, atrophy developed in the bilateral thalami and the right frontal cortex<sup>30</sup>. Similarly *Sepulcre* et al. found no focal grey matter atrophy in 31 primary progressive MS (PPMS) subjects, except in the cerebellum when not correcting for multiple comparisons<sup>31</sup>. Nevertheless, if a specific pattern of grey matter atrophy is to be tentatively established, then the thalamus is invariably affected, as well as the temporal, insular and frontal lobes (often sensory-motor cortex).

The location of white matter lesions in MS or the total lesion load only moderately correlate with clinical symptoms and cognitive impairment (clinic-radiological paradox<sup>32</sup>). Several reports suggested that disability has a closer relationship with grey matter atrophy<sup>33</sup>. However, upon closer inspection of these studies, using VBM approach correlation between focal atrophy and disability was identified infrequently. *Audoin* found correlation between expanded disability status scale (EDSS<sup>34</sup>) and focal atrophy in the cerebellum<sup>35</sup>. With regard to the cognitive performance, *Morgen* and co-workers found extensive correlation with paced auditory serial addition test (PASAT) scores<sup>36</sup>. *Cerasa* and colleagues, using many cognitive tests, only found correlation with performance on symbol digit modalities (SDM) and controlled oral word association test (COWAT)<sup>37</sup>.

Moreover, global grey matter atrophy was found to correlate with the clinical features of the disease as measured via the EDSS<sup>19, 25, 26, 38, 39</sup> and cognitive function tests<sup>39–42</sup>.

## Pathology and pathophysiology of grey matter injury in multiple sclerosis

The methods for detecting grey matter pathology are especially important, considering the grey matter demyelination in MS. *Gilmore* et al. reported an “overall 28.8% of the grey matter demyelinated as compared with only 15.6% of the white matter”<sup>7</sup>. Most of this demyelination (about 60%) is subpial<sup>6</sup> and is present in the form of ribbon like demyelination often affecting several adjacent gyri. Importantly, based on post-mortem MRI imaging of three MS cases there was no association between the cortical demyelination and the focal or diffuse white matter pathology<sup>43</sup>. The various mechanisms behind the lesions are indicated by the fact that in contradistinction to the white matter lesions, in cortical lesions there is no inflammatory cell infiltration and foamy macrophages, immunoglobulin deposition or complement activation is scarce<sup>44, 45</sup>. Meninges were also shown to be affected in MS<sup>46, 47</sup>, B-cell follicle-like structures were described in the inflamed meninges. More recently this meningeal inflammation was hypothesized to be the major contributor to the cortical pathology: the B-cell follicle-like structures were associated with increased subpial demyelination and cortical atrophy<sup>48</sup>. Apart from the demyelination, a gradient of neuronal loss was observed in the affected cortex, which was accompanied by astrocyte loss and opposite to this gradient a microglia activation<sup>48</sup>. These changes were suggested to be consistent with a non-targeted general immunopathological response

**Table 1.** Correlation of grey matter atrophy and clinical signs and cognitive impairment

Study	Type	EDSS	DD	Comment
36	19 RR	1 (0-3.5)*	13m (2-60)*	No correlation with EDSS. Extensive correlation with PASAT.
30	21 RR	1 (0-3)*	25.8m (14-45)*	No difference patients vs. controls. Over two years larger change developed in the thalami and left frontal region.
89	51 RR	2.6 (1.5-4.5)**	13.1m (4-34)**	Left lateralised group difference. No correlation with EDSS. Right caudate correlate with LL.
90	28 CIS	0* (0-1)	0y** (0)	No difference controls vs. CIS. Other groups were not compared to controls. Pairwise comparisons yielded widespread differences. LL correlate with thalamic volume in RRMS. No correlation with EDSS or DD
	26 RR	1 (0-3)	9y (2-22)	
	27 SPMS	6 (4-8)	17.6y (3-41)	
	18 PPMS	5.5 (4-7.5)	8.5y (2-18)	No correlation between atrophy and clinical (EDSS, MSFC, NHPT and TWT) or cognitive performance (PASAT). These measures correlated with regional MTR.
91	46 PPMS	4.5 (1.5-7)*	3.3y (2-5)	No difference between controls and patients (only in the thalamus, when not corrected for multiple correlations). Anterior thalamic grey matter correlated with lesion load. One-year longitudinal study found reduced GM volume in several basal ganglia structures and in some cortical areas.
31	31 PPMS	4.5 (3.5-7)	3y (2-5)	Group difference in the left inferior frontal gyrus and lateral occipital cortex.
92	15 RR	2* (0-3.5)	7.3y** ± 6.5	Patients with and without cerebellar symptoms were examined. Thalamic atrophy, plus putamen and primary motor cortex in the cerebellar group. No correlation with EDSS. SDM and COWAT test showed correlation in the two groups separately. No correlation with other cognitive tests measuring verbal and spatial memory, visuo-spatial processing and abstract/conceptual reasoning
37	26 RR	RRc 2.5* (1-4)	RRc 12.1 ± 8.7	Widespread differences between controls and patients. Cognitive tests on the following domains: Information processing, speed, attention, working memory, verbal memory, Visuo-spatial memory and function, visuo-constructive abilities, executive function, general intelligence. VBM found correlation SDM and CVLT-LDCR.
	12 RRc	RRnc 2 (1.5-4.5)	RRnc 8.8 ± 4.4	
	14 RRnc			
93	13 RR	3 (1-6.5)	15 ± 7**	Study compares normal controls, RRSM and NMO patients. Widespread differences between controls and patients. No correlation with DD and EDSS. LL correlated with GM volume of the right caudate and bilateral thalami.
5	SPMS			Mainly subcortical atrophy (thalamus, caudate, nucl. Lenticularis, hippocampus), but some frontal, temporal posterior cingulate and cerebellar cortical atrophy. Thalamic atrophy correlated with LL. Cerebellar atrophy correlated with EDSS.
94	26 RR	3* (1-6)	56.3** (6-240)	Thalamic atrophy that disappeared after correction for multiple correlation
	26 NMO			Diffuse grey matter atrophy. Longitudinal analysis also performed. FSL-VBM and SPM-VBM was used.
35	62 CIS	1* (0-3.5)	4m (0-6)	Atrophy in the sensory motor cortex, thalamus, temporal lobe insula.
95	34 CIS	1.5* (0-3)	<3m	No correlation between regional atrophy and age, DD, EDSS or MSFC. No correlation with performance on neuropsychological tests (TMTA, TMTB, SDM, DST, RAVLT-DR and DST)
96	59 RR	1.5* (0-5)	1.8y* (0.1-17)	
97	36 PPMS	4.5* (1.5-7)	3.3 ± 0.9	
98	PPMS 2	6* (3-7.5)	14.43** ± 8.89	
	RR 3			
	SPMS 10			
99	21 RR	3.5* (0-85)	10.1** ± 5.1	Grey matter atrophy in the thalamus, hypothalamus, caudate and frontal lobe. No correlation with clinical measures and focal atrophy is reported to be investigated.
100	11 PPMS			
	26 RR	1.2 ± 0.9**	8.5** ± 5.9	GM loss in the bilateral thalami and caudate nuclei. No correlation found between GM atrophy and EDSS.

\*median (range), \*\*mean (range or STD), y: year, m: month, RRc: RRSM patients with cerebellar symptoms, RRnc: RRSM patients without cerebellar symptoms, SDM symbol digit modalities, COWAT: Controlled Oral Word Association Test, MSFC: Multiple sclerosis functional composite, TMTA and B: Trial making test A and B, DST: Digit span test, RAVLT-DR: Rey's Auditory Verbal Learning Test Delayed Recall, NMO: Neuromyelitis optica

mediated by the CD8+ T cells via cytotoxic tissue damage or indirectly through the activation of microglia. Furthermore, neuronal loss was found in layers III and V in regions where no B-cell follicle-like structures were detected, this suggests that other mechanisms are also involved in the atrophy. Neurodegeneration due to inflammatory insults in downstream white matter tracts, reduced synaptic and glial density may also contribute to the atrophy<sup>49, 50</sup>.

Various mechanisms were proposed behind the neurodegeneration in MS. Neuroinflammation can directly induce apoptosis through various cytokines and the oxidative burst arising from the activated microglia may also contribute<sup>51</sup>. As in many neurodegenerative diseases<sup>52</sup>, oxidative stress and mitochondrial dysfunction are proposed to be a major mediators of neurodegeneration and axonal loss in MS<sup>53–55</sup>. Another key component in MS neurodegeneration is glutamate excitotoxicity<sup>56</sup> and recently a link between inflammation and excitotoxicity was established<sup>57</sup>. Furthermore, a possible mechanism of neurodegeneration might be an imbalance of neuroprotective and neurotoxic agents, such as the metabolites of the kynurenine pathway a major biochemical pathway in tryptophan metabolism<sup>58–60</sup>.

## Grey matter atrophy as a biomarker for therapeutic efficacy

It is becoming progressively more evident that grey matter atrophy is a stronger predictor of disability progression in MS than white matter pathology. Moreover, it may also be used as a complementary MRI method for disease progression instead of conventional MRI techniques<sup>25, 39, 61–63</sup>. Thus, making it a promising biomarker for therapeutic response in pharmacological studies.

### INTRAMUSCULAR INTERFERON $\beta$ -1A

A post hoc analysis of the MRI images from 140 patients (72 in the placebo arm, 68 in the treatment arm) participating in a phase III clinical trial of intramuscular interferon $\beta$ -1a (INF $\beta$ -1a, Avonex) showed a reduced rate of the atrophy (brain parenchymal fraction) in the treatment arm<sup>64</sup>. While there was no difference between the two treatment groups in the first year of treatment, during the second year INF $\beta$ -1a reduced the rate of atrophy by 55%. In a subsequent study, treatment over two years with intramuscular, subcutaneous INF $\beta$ -1a and glatiramer acetate (GA) resulted in a decreased

rate of reduction in brain gray matter fraction<sup>65</sup>. A three-year period open-label study using intramuscular INF $\beta$ -1a found a reduced whole-brain and GM atrophy, as well as of T1-hypointense lesion volume accumulation in the treatment group<sup>66</sup>. When compared to year one weekly intramuscular INF $\beta$ -1a treatment data, the atrophy rate was reduced in the second and third year of treatment<sup>74</sup>. Subsequent analysis of a 138 patients subgroup having frequent MRI scans, showed that the majority of the atrophy during the first year (approximately 70%) occurred during the first four months<sup>74</sup>.

### INTERFERON $\beta$ -1B

Five years post INF $\beta$ -1b clinical trials for patients with PPMS, not only were motor and cognitive performance better, but also the decrease of brain parenchymal fraction was similarly smaller<sup>75</sup>. In an earlier randomized study, which measured the parenchymal volumes only in the central slab failed to demonstrate a beneficial effect of INF $\beta$ -1b<sup>76</sup>. A smaller open-label study with RRMS patients also failed to demonstrate completely the beneficial effect of INF $\beta$ -1b, a reduced rate of atrophy was observed only in the second year, but not in the first or third years of treatment<sup>77</sup>.

### SUBCUTANEOUS INTERFERON $\beta$ -1A

In the PRISM trial neither high dose nor low dose (22 and 44  $\mu$ g three times weekly) INF $\beta$ -1a–Rebif showed a beneficial effect against reduction of the whole brain volume<sup>78</sup>. In contrast, in the ETOMS study, subcutaneous INF $\beta$ -1a (once weekly 22  $\mu$ g) given to patients after the first attack, not only delayed the appearance of a second relapse but also reduced the rate of atrophy over two years as measured with SIENA<sup>67</sup>. Furthermore, in a comparative study, glatiramer acetate, intramuscular and subcutaneous INF $\beta$ -1a was superior to placebo in reducing brain atrophy at 24 months, while no difference between treatment outcomes was detected<sup>65</sup>. In Gasperini's study there was no difference in brain atrophy using 11  $\mu$ g and 33  $\mu$ g subcutaneous INF $\beta$ -1b treatment (three times weekly)<sup>79</sup>.

### GLATIRAMER ACETATE

In the open-label extension of the US GA trial, the patients who were in the placebo arm originally had more brain volume loss as compared to subjects receiving glatiramer acetate (GA) treatment<sup>80</sup>. Kahn and co-workers showed a significantly reduced loss

**Table 2.** *The effect of treatment on grey matter atrophy*

	First year	Second year	First two years
INFβ-1a i.m.	X <sup>64</sup>	✓ <sup>64</sup>	✓ <sup>64-66+++</sup>
INFβ-1b	–	–	–
INFβ-1a s.c.	–	–	✓ <sup>65, 67</sup>
GA	X <sup>68, 69</sup>	X <sup>††68, 69</sup>	✓ <sup>65, 70</sup>
Natalizumab	X <sup>71†</sup>	✓ <sup>71</sup>	X <sup>71</sup>
Fingolimod	✓ <sup>72, 73++++</sup>	✓ <sup>73</sup>	✓ <sup>73</sup>

†pseudoatrophy, †18 months, ††three years, †††at six months also

of brain volume in patients receiving disease-modifying therapy<sup>81</sup> and having only minor progression in their disability (EDSS). Ge and colleagues found reduced rates of brain tissue loss over 24 months of GA treatment in comparison to placebo treated subjects<sup>70</sup>. Conversely, a nine months placebo controlled study showed no significant benefit of GA on brain atrophy<sup>68</sup>. Importantly, in a comparative study GA reduced the rate of atrophy more than low and high doses of INFβ-1a<sup>81</sup>, while low dose INFβ-1a was more effective than high dose<sup>81</sup>. However, Calabrese found the use of GA, intramuscular INFβ-1a or subcutaneous INFβ-1a similarly effective in reducing grey matter atrophy<sup>65</sup>.

#### NATALIZUMAB

While natalizumab is effective in reducing MRI-measured disease activity (T2 lesion load and enhancing lesions) the results on brain atrophy are controversial<sup>71</sup>. In the first year of natalizumab treatment a pseudoatrophy appears, which over the next two years converts to a significant reduction of brain volume reduction<sup>71, 82</sup>. This phenomenon was related to the cessation of inflammatory activity.

In comparative studies natalizumab was more effective in reducing grey matter atrophy. The analysis of the secondary and the tertiary MRI measures in the SENTINEL study showed that among beneficial effect of combined intramuscular INFβ-1a and natalizumab (T2 lesion volume, T1 hypointense lesions, enhancing lesions) treatment the atrophy rate was reduced when compared to the group receiving INFβ-1a alone<sup>83</sup>. In RRMS patients enrolled in a non-randomised pilot study, significantly lower changes in brain parenchymal volume were recorded in those treated with natalizumab (n=12) in comparison to those receiving INFβ (n=14)<sup>84</sup>. In a two-year-prospective study natalizumab was also superior to the immunomodulatory agents GA and INFβ in reducing the accumulation of cortical lesions as well as cortical atrophy<sup>85</sup>.

#### FINGOMILOD

Fingolimod is a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes: it has shown clinical efficacy in phase II<sup>86</sup> and III clinical trials<sup>72</sup>. The efficacy of the drug was also proved with paraclinical measures. New T2 lesions as well as the number of gadolinium enhancing lesions were reduced in the group receiving fingolimod when compared to patients receiving intramuscular INFβ<sup>72, 86</sup>. While in a six-month phase II study, there was no improvement in the rate of brain atrophy as compared to placebo arm<sup>86</sup>. However, the 12 months phase III study (TRANSFORMS) revealed significant improvement in the brain atrophy rate in comparison to intramuscular INFβ treatment<sup>72</sup>, this effect was evident in the subgroup analysis also<sup>87</sup>. Phase III (FREEDOMS) study showed significant reduction of brain atrophy rate in fingolimod treated patients at 6, 12 and 24 months<sup>73</sup>. Interestingly, this effect was unrelated to the T2 lesion load or the number of enhancing lesions (**Table 2.**)<sup>88</sup>.

## Conclusions

Paraclinical examinations in the diagnosis of MS such as MRI have a central role. However it is important that conventional MRI modalities cannot identify the full range of abnormalities. Sophisticated analysis approaches have to complement the expert eye of physician and advanced neuroimaging have to complement traditional neuroradiology in order to further elucidate the disease pathomechanism and tailor treatment efficacy.

#### ACKNOWLEDGEMENTS

*The paper was supported by MTA-SZTE Neuroscience Research Group, Szeged, Hungary, project FNUSA- ICRC (no. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund, an*

OTKA [PD 104715] grant, the National Brain Research Program (Grant No. KTIA\_13\_NAP-A-II/20.) and by the European Union and co-funded by the European Social Fund (Project titles: "Telemedicine-focused research activities in the

field of Mathematics, Informatics and Medical sciences" - TAMOP-4.2.2.A-11/1/KONV-2012-0073 and "National Excellence Program" - TAMOP-4.2.4.A/ 2-11/1-2012-0001.). We thank Anne Frawley for the English editing.

## REFERENCES

1. Keegan BM, Noseworthy JH. Multiple sclerosis. *Annu Rev Med* 2002;53:285-302.
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol* 2005;58:840-6.
3. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 1962;25:315-20.
4. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain* 2005;128:2705-12.
5. Bo L, Geurts JJ, Mork SJ, van der Valk P. Grey matter pathology in multiple sclerosis. *Acta neurologica Scandinavica. Supplementum* 2006;183:48-50.
6. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. *Journal of Neuropathology and Experimental Neurology* 2003;62:723-2.
7. Gilmore CP, Donaldson I, Bo L, et al. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. *Journal of Neurology, Neurosurgery, and Psychiatry* 2009;80:182-7.
8. Vercellino M, Plano F, Votta B, et al. Grey matter pathology in multiple sclerosis. *J Neuropathol Exp Neurol* 2005;64:1101-7.
9. Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. *Brain Pathol* 2007;17:38-44.
10. Turetschek K, Wunderbaldinger P, Bankier AA, et al. Double inversion recovery imaging of the brain: initial experience and comparison with fluid attenuated inversion recovery imaging. *Magn Reson Imaging* 1998;16:127-35.
11. Geurts JJ, Pouwels PJ, Uitendaele BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. *Radiology* 2005;236:254-60.
12. Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. *Neurology* 2012;78:302-8.
13. Geurts JJ, Roosendaal SD, Calabrese M, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. *Neurology* 2011;76:418-24.
14. Nakamura K, Fisher E. Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients. *Neuroimage* 2009;44:769-76.
15. Ashburner J, Friston K. Multimodal image coregistration and partitioning—a unified framework. *Neuroimage* 1997;6:209-17.
16. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. *Journal of Computer Assisted Tomography* 2001;25:466-75.
17. Smith S, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. *NeuroImage* 2004;23 Suppl 1:S208-219.
18. Filippi M, Mastronardo G, Rocca MA, Pereira C, Comi G. Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis. *Journal of the Neurological Sciences* 1998;158:148-53.
19. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. *Neurology* 2003;60:1157-62.
20. Sharma J, Sanfilippo MP, Benedict RH, et al. Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. *AJNR. American Journal of Neuroradiology* 2004;25:985-96.
21. Bermel RA, Sharma J, Tjoa CW, Puli SR, Bakshi R. A semi-automated measure of whole-brain atrophy in multiple sclerosis. *Journal of the Neurological Sciences* 2003;208:57-65.
22. Vrenken H, Geurts JJ, Knol DL, et al. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. *Radiology* 2006;240:811-20.
23. Kassubek J, Tumani H, Ecker D, et al. Age-related brain parenchymal fraction is significantly decreased in young multiple sclerosis patients: a quantitative MRI study. *Neuroreport* 2003;14:427-30.
24. Chard DT, Griffin CM, Parker GJ, et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. *Brain: a journal of neurology* 2002;125:327-37.
25. Sanfilippo MP, Benedict RH, Sharma J, Weinstock-Guttman B, Bakshi R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. *NeuroImage* 2005;26:1068-77.
26. Tedeschi G, Lavorgna L, Russo P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. *Neurology* 2005;65:280-5.
27. Sanfilippo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. *Neurology* 2006;66:685-92.
28. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. *Brain: a journal of neurology* 2005;128:1454-60.
29. Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. *Neurology* 2005;64:1001-7.
30. Audoin B, Davies GR, Finisku L, et al. Localization of grey matter atrophy in early RRMS: A longitudinal study. *Journal of Neurology* 2006;253:1495-501.
31. Sepulcre J, Sastre-Garriga J, Cercignani M, et al. Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. *Archives of Neurology* 2006;63:1175-80.
32. Kincses ZT, Ropele S, Jenkinson M, et al. Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis. *Multiple Sclerosis* 2011;17:681-9.

33. *Geurts JJ, Calabrese M, Fisher E, Rudick RA.* Measurement and clinical effect of grey matter pathology in multiple sclerosis. *Lancet Neurology* 2012;11:1082-92.
34. *Kurtzke JF.* Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983;33:1444-52.
35. *Audoin B, Zaaaraoui W, Reuter F, et al.* Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. *Journal of Neurology, Neurosurgery, and psychiatry* 2010;81:690-5.
36. *Morgen K, Sammer G, Courtney SM, et al.* Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. *NeuroImage* 2006;30:891-8.
37. *Cerasa A, Valentino P, Chiriacio C, et al.* MR imaging and cognitive correlates of relapsing-remitting multiple sclerosis patients with cerebellar symptoms. *Journal of Neurology* 2013;260:1358-66.
38. *Fisniku LK, Chard DT, Jackson JS, et al.* Gray matter atrophy is related to long-term disability in multiple sclerosis. *Annals of Neurology* 2008;64:247-54.
39. *Roosendaal SD, Bendfeldt K, Vrenken H, et al.* Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. *Multiple Sclerosis* 2011;17:1098-106.
40. *Amato MP, Bartolozzi ML, Zipoli V, et al.* Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. *Neurology* 2004;63:89-93.
41. *Calabrese M, Agosta F, Rinaldi F, et al.* Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. *Archives of Neurology* 2009;66:1144-50.
42. *Batista S, Zivadinov R, Hoogs M, et al.* Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. *Journal of Neurology* 2012;259:139-46.
43. *Bo L, Geurts JJ, van der Valk P, Polman C, Barkhof F.* Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. *Archives of Neurology* 2007;64:76-80.
44. *Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ.* Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. *Multiple Sclerosis* 2003;9:323-31.
45. *Brink BP, Veerhuis R, Breij EC, et al.* The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. *Journal of Neuropathology and Experimental Neurology* 2005;64:147-55.
46. *Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F.* Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. *Brain Pathology* 2004;14:164-74.
47. *Magliozzi R, Howell O, Vora A, et al.* Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain : a journal of neurology* 2007;130:1089-104.
48. *Magliozzi R, Howell OW, Reeves C, et al.* A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. *Annals of Neurology* 2010;68:477-93.
49. *Frischer JM, Bramow S, Dal-Bianco A, et al.* The relation between inflammation and neurodegeneration in multiple sclerosis brains. *Brain : a Journal of Neurology* 2009;132:1175-89.
50. *Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM.* Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. *Neurology* 2006;67:960-7.
51. *Gebicke-Haerter PJ.* Microglia in neurodegeneration: molecular aspects. *Microscopy research and Technique* 2001;54:47-58.
52. *Kincses ZT, Vecsei L.* Pharmacological therapy in Parkinson's disease: focus on neuroprotection. *CNS neuroscience & Therapeutics* 2011;17:345-67.
53. *van Horssen J, Witte ME, Ciccarelli O.* The role of mitochondria in axonal degeneration and tissue repair in MS. *Multiple Sclerosis* 2012;18:1058-67.
54. *Campbell GR, Ziabreva, I, Reeve AK, et al.* Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. *Annals of Neurology* 2011;69:481-92.
55. *Dutta R, McDonough J, Yin X, et al.* Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. *Annals of Neurology* 2006;59:478-89.
56. *Gonsette RE.* Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. *Journal of the Neurological Sciences* 2008;274:48-53.
57. *Degos V, Peineau S, Nijboer C, et al.* G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration. *Annals of Neurology* 2013.
58. *Vecsei L, Szalardy L, Fulop F, Toldi J.* Kynurenes in the CNS: recent advances and new questions. *Nature reviews. Drug Discovery* 2013;12:64-82.
59. *Rajda C, Bergquist J, Vecsei L.* Kynurenes, redox disturbances and neurodegeneration in multiple sclerosis. *Journal of Neural Transmission* 2007;(suppl.):323-9.
60. *Hartai Z, Klivenyi P, Janaky T, et al.* Kynurenine metabolism in multiple sclerosis. *Acta Neurologica Scandinavica* 2005;112:93-6.
61. *Horakova D, Dwyer MG, Havrdova E, et al.* Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. *Journal of the Neurological Sciences* 2009;282:112-9.
62. *Fisher E, Rudick RA, Cutter G, et al.* Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. *Multiple Sclerosis* 2000;6:373-7.
63. *Fisher E, Rudick RA, Simon JH, et al.* Eight-year follow-up study of brain atrophy in patients with MS. *Neurology* 2002;59:1412-20.
64. *Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L.* Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. *Multiple Sclerosis Collaborative Research Group.* *Neurology* 1999;53:1698-704.
65. *Calabrese M, Bernardi V, Atzori M, et al.* Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. *Multiple Sclerosis* 2012;18:418-24.
66. *Zivadinov R, Locatelli L, Cookfair D, et al.* Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. *Multiple Sclerosis* 2007;13:490-501.
67. *Filippi M, Rovaris M, Inglese M, et al.* Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2004;364:1489-96.
68. *Comi G, Filippi M, Wolinsky JS.* European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. *European/Canadian Glatiramer Acetate Study Group.* *Annals of Neurology* 2001;49:290-7.
69. *Rovaris M, Comi G, Rocca MA, et al.* Short-term brain vol-

- ume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. *Brain : a journal of neurology* 2001;124:1803-12.
70. *Ge Y, Grossman RI, Udupa JK, et al.* Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. *Neurology* 2000;54:813-7.
  71. *Miller DH, Soon D, Fernando KT, et al.* MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. *Neurology* 2007;68:1390-401.
  72. *Cohen JA, Barkhof F, Comi G, et al.* Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *The New England journal of Medicine* 2010;362:402-15.
  73. *Kappos L, Radue EW, O'Connor P, et al.* A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *The New England Journal of Medicine* 2010;362:387-401.
  74. *Hardmeier M, Wagenpfeil S, Freitag P, et al.* Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. *Neurology* 2005;64:236-40.
  75. *Tur C, Montalban X, Tintore M, et al.* Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. *Archives of Neurology* 2011;68:1421-7.
  76. *Molyneux PD, Kappos L, Polman C, et al.* The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. *European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain: a journal of neurology* 2000;123(Pt 11):2256-63.
  77. *Frank JA, Richert N, Bash C, et al.* Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. *Neurology* 2004;62:719-25.
  78. *Jones CK, Riddehough A, Zhao G, Paty DW.* MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial. *Neurology* 2001;(Suppl. 3.):A379.
  79. *Gasperini C, Paolillo A, Giugni E, et al.* MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. *Multiple Sclerosis* 2002; 8:119-23.
  80. *Wolinsky JS, Narayana PA, Johnson KP, Multiple Sclerosis Study, G, the, M. R. I. A. C.* United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. *Multiple Sclerosis Study Group and the MRI Analysis Center. Multiple Sclerosis* 2001;7:33-41.
  81. *Khan O, Bao F, Shah M, et al.* Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. *Journal of the Neurological Sciences* 2012;312:7-12.
  82. *Magraner M, Coret F, Casanova B.* The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. *European Journal of radiology* 2012;81:3485-90.
  83. *Radue EW, Stuart WH, Calabresi PA, et al.* Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. *Journal of the Neurological Sciences* 2010;292:28-35.
  84. *Portaccio E, Stromillo ML, Goretti B, et al.* Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. *European journal of neurology : the official journal of the European Federation of Neurological Societies* 2013;20:986-90.
  85. *Rinaldi F, Calabrese M, Seppi D, et al.* Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. *Multiple sclerosis* 2012;18: 1760-7.
  86. *Kappos L, Antel J, Comi G, et al.* Oral fingolimod (FTY720) for relapsing multiple sclerosis. *The New England Journal of Medicine* 2006;355:1124-40.
  87. *Cohen JA, Barkhof F, Comi G, et al.* Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. *Journal of Neurology* 2013.
  88. *Radue EW, O'Connor P, Polman CH, et al.* Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. *Archives of Neurology* 2012;69:1259-69.
  89. *Prinster A, Quarantelli M, Orefice G, et al.* Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. *NeuroImage* 2006;29:859-67.
  90. *Ceccarelli A, Rocca MA, Pagani E, et al.* A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. *NeuroImage* 2008;42:315-22.
  91. *Khaleeli Z, Cercignani M, Audoin B, et al.* Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. *NeuroImage* 2007;37:253-61.
  92. *Jehna M, Langkammer C, Khalil M, et al.* An exploratory study on the spatial relationship between regional cortical volume changes and white matter integrity in multiple sclerosis. *Brain Connectivity* 2013.
  93. *Nocentini U, Bozzali M, Spano B, et al.* Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis. *Brain Imaging and Behavior* 2012.
  94. *Duan Y, Liu Y, Liang P, et al.* Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study. *European Journal of Radiology* 2012;81:e110-4.
  95. *Raz E, Cercignani M, Sbardella E, et al.* Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. *Radiology* 2010;254:227-34.
  96. *Battaglini M, Giorgio A, Stromillo ML, et al.* Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. *Journal of the Neurological Sciences* 2009;282:55-60.
  97. *Bodini B, Khaleeli Z, Cercignani M, et al.* Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM. *Human Brain Mapping* 2009;30:2852-61.
  98. *Sastre-Garriga J, Arevalo MJ, Renom, M, et al.* Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis. *Journal of the Neurological Sciences* 2009;282:120-4.
  99. *Senda J, Watanabe H, Tsuboi T, et al.* MRI mean diffusivity detects widespread brain degeneration in multiple sclerosis. *Journal of the Neurological Sciences* 2012;319:105-10.
  100. *Ceccarelli A, Jackson JS, Tauhid S, et al.* The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. *AJNR American Journal of Neuroradiology* 2012;33:1579-85.